Literature DB >> 9414138

Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation.

M Shichijo1, Y Shimizu, K Hiramatsu, N Inagaki, K Tagaki, H Nagai.   

Abstract

Human peripheral blood basophils are known to secrete interleukin (IL)-4 and IL-13 after cross-linking of cell surface IgE. However, little is known about the pharmacological regulation of allergic cytokine release from basophils. In the present study, we investigated the effects of cyclic 3',5'-adenosine monophosphate (cAMP)-elevating agents on antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparations. We obtained venous blood from 27 atopic asthmatic patients (mean age was 45.8+/-3.6 years, all patients were sensitive to mite antigen) and prepared basophil-enriched leukocyte preparations by double-Percoll gradients (basophil purity was 13.4+/-1.6%). The cell preparations were treated with phosphodiesterase (PDE) inhibitors, dexamethasone, forskolin or dibutyryl cAMP for 10 min and were challenged with mite antigen for 6 h. The released IL-4 and IL-13 in the supernatants were measured by enzyme-linked immunosorbent assay systems. No IL-4 or IL-13 was detected in the supernatant of the basophil-depleted preparation after the challenge with mite antigen, suggesting that basophils specifically produce these cytokines. A nonselective PDE inhibitor, theophylline, and a PDE IV-selective inhibitor, rolipram, significantly suppressed the release of IL-4 and IL-13 from the basophil-enriched preparation. Although several concentrations of cilostazol, a PDE III-selective inhibitor, had no effect on the release of both cytokines, cilostazol suppressed the release of IL-4 additively when applied with rolipram. Forskolin and dibutyril cAMP also significantly suppressed the release of both cytokines, suggesting that the suppressive effects by PDE inhibitors were accompanied by the elevations in cAMP levels. We conclude that basophil-enriched leukocyte preparations produce IL-4 and IL-13 in response to antigen and that the release of these cytokines could be regulated by cAMP-modulating agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414138     DOI: 10.1159/000237693

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  5 in total

1.  Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.

Authors:  N Yoshida; Y Shimizu; K Kitaichi; K Hiramatsu; M Takeuchi; Y Ito; H Kume; K Yamaki; R Suzuki; E Shibata; T Hasegawa; K Takagi
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells.

Authors:  Nahid Eskandari; Fatemeh Tashrifi; Reza Bastan; Alrieza Andalib; Zahra Yousefi; Peter T Peachell
Journal:  Int J Immunopathol Pharmacol       Date:  2016-01-18       Impact factor: 3.219

3.  Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.

Authors:  A Kamachi; M Munakata; Y Nasuhara; M Nishimura; Y Ohtsuka; M Amishima; T Takahashi; Y Homma; Y Kawakami
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

4.  Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils.

Authors:  Nahid Eskandari; Thulani Wickramasinghe; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

5.  Modulation of mTOR effector phosphoproteins in blood basophils from allergic patients.

Authors:  Yael Gernez; Rabindra Tirouvanziam; Neha Reshamwala; Grace Yu; Brittany C Weldon; Stephen J Galli; Leonore A Herzenberg; Kari C Nadeau
Journal:  J Clin Immunol       Date:  2012-02-21       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.